Primecap Management Co. CA Increases Stock Holdings in Xencor, Inc. $XNCR

Primecap Management Co. CA increased its stake in shares of Xencor, Inc. (NASDAQ:XNCR) by 1.4% during the 3rd quarter, according to its most recent filing with the SEC. The institutional investor owned 10,675,022 shares of the biopharmaceutical company’s stock after acquiring an additional 147,700 shares during the period. Primecap Management Co. CA owned approximately 0.15% of Xencor worth $125,218,000 at the end of the most recent reporting period.

Several other large investors also recently bought and sold shares of XNCR. Hantz Financial Services Inc. lifted its position in shares of Xencor by 209.1% during the third quarter. Hantz Financial Services Inc. now owns 3,187 shares of the biopharmaceutical company’s stock worth $37,000 after purchasing an additional 2,156 shares in the last quarter. GAMMA Investing LLC increased its stake in Xencor by 77.1% during the 3rd quarter. GAMMA Investing LLC now owns 3,328 shares of the biopharmaceutical company’s stock worth $39,000 after buying an additional 1,449 shares during the period. Farther Finance Advisors LLC purchased a new stake in Xencor during the 3rd quarter worth $44,000. Tower Research Capital LLC TRC lifted its holdings in Xencor by 118.4% in the 2nd quarter. Tower Research Capital LLC TRC now owns 5,568 shares of the biopharmaceutical company’s stock worth $44,000 after buying an additional 3,018 shares in the last quarter. Finally, Federated Hermes Inc. boosted its position in Xencor by 114.3% in the 3rd quarter. Federated Hermes Inc. now owns 3,947 shares of the biopharmaceutical company’s stock valued at $46,000 after buying an additional 2,105 shares during the last quarter.

Insider Transactions at Xencor

In related news, CEO Bassil I. Dahiyat sold 114,377 shares of the stock in a transaction dated Friday, December 19th. The shares were sold at an average price of $15.71, for a total transaction of $1,796,862.67. Following the sale, the chief executive officer owned 466,635 shares in the company, valued at $7,330,835.85. This represents a 19.69% decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available through this hyperlink. Also, VP John R. Desjarlais sold 73,367 shares of Xencor stock in a transaction that occurred on Friday, December 19th. The shares were sold at an average price of $15.72, for a total value of $1,153,329.24. Following the completion of the transaction, the vice president owned 236,574 shares of the company’s stock, valued at approximately $3,718,943.28. The trade was a 23.67% decrease in their ownership of the stock. The disclosure for this sale is available in the SEC filing. Company insiders own 4.76% of the company’s stock.

Wall Street Analyst Weigh In

Several research analysts recently commented on the company. Weiss Ratings reiterated a “sell (d-)” rating on shares of Xencor in a research note on Monday, December 29th. Royal Bank Of Canada lifted their price objective on Xencor from $18.00 to $19.00 and gave the stock an “outperform” rating in a report on Thursday, November 6th. Barclays upped their target price on Xencor from $26.00 to $27.00 and gave the company an “overweight” rating in a research report on Thursday. Truist Financial began coverage on shares of Xencor in a research note on Monday, November 24th. They issued a “buy” rating and a $29.00 price target for the company. Finally, JPMorgan Chase & Co. cut their price target on shares of Xencor from $20.00 to $18.00 and set an “overweight” rating on the stock in a report on Thursday, November 6th. Eight research analysts have rated the stock with a Buy rating, one has assigned a Hold rating and one has issued a Sell rating to the company’s stock. Based on data from MarketBeat.com, the stock has an average rating of “Moderate Buy” and an average target price of $25.00.

Xencor Trading Up 13.1%

Shares of XNCR opened at $13.55 on Friday. Xencor, Inc. has a 52 week low of $6.92 and a 52 week high of $18.69. The firm has a market cap of $967.61 million, a price-to-earnings ratio of -10.93 and a beta of 0.98. The stock has a 50 day moving average of $13.21 and a 200-day moving average of $12.74.

Xencor (NASDAQ:XNCR) last announced its quarterly earnings data on Wednesday, February 25th. The biopharmaceutical company reported ($0.09) earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.64) by $0.55. The firm had revenue of $28.24 million for the quarter, compared to analysts’ expectations of $29.97 million. Xencor had a negative return on equity of 14.62% and a negative net margin of 73.20%.The firm’s revenue for the quarter was down 46.6% on a year-over-year basis. During the same period last year, the business posted ($0.62) earnings per share. On average, sell-side analysts predict that Xencor, Inc. will post -3.68 earnings per share for the current fiscal year.

Xencor Profile

Xencor, Inc is a clinical-stage biopharmaceutical company focused on the design and development of engineered protein therapeutics for the treatment of autoimmune diseases, cancer and neurological disorders. The company applies its proprietary XmAb® platform to manipulate antibody structure and function, creating molecules with enhanced immune engagement and extended half-life. Xencor’s research programs span a range of therapeutic modalities, including monoclonal antibodies, bispecific antibodies and cytokine-based fusion proteins.

The XmAb® platform enables precise modification of the Fc region to augment key properties such as receptor binding, effector function and pharmacokinetics.